Pathstone Holdings LLC Sells 3,885 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Pathstone Holdings LLC lowered its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 5.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 69,154 shares of the medical equipment provider's stock after selling 3,885 shares during the period. Pathstone Holdings LLC's holdings in Zimmer Biomet were worth $7,298,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Franklin Resources Inc. lifted its position in shares of Zimmer Biomet by 398.7% in the 4th quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider's stock worth $369,469,000 after purchasing an additional 2,796,372 shares during the period. Norges Bank bought a new position in shares of Zimmer Biomet in the 4th quarter worth about $216,223,000. Dodge & Cox boosted its stake in Zimmer Biomet by 12.0% during the fourth quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider's stock worth $2,019,480,000 after acquiring an additional 2,044,645 shares in the last quarter. Nuveen Asset Management LLC grew its holdings in Zimmer Biomet by 191.8% in the fourth quarter. Nuveen Asset Management LLC now owns 1,389,405 shares of the medical equipment provider's stock worth $146,763,000 after purchasing an additional 913,310 shares during the period. Finally, Sound Shore Management Inc. CT bought a new position in shares of Zimmer Biomet during the fourth quarter valued at approximately $81,447,000. 88.89% of the stock is owned by institutional investors.

Insider Activity

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the sale, the senior vice president now owns 8,768 shares of the company's stock, valued at $915,379.20. The trade was a 14.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 1.39% of the company's stock.

Wall Street Analysts Forecast Growth

ZBH has been the subject of a number of recent research reports. BTIG Research reiterated a "buy" rating on shares of Zimmer Biomet in a research note on Monday, April 14th. Morgan Stanley reduced their price target on shares of Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Needham & Company LLC reaffirmed a "hold" rating on shares of Zimmer Biomet in a research report on Friday, February 7th. JMP Securities reduced their target price on Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating for the company in a report on Wednesday, May 7th. Finally, Stifel Nicolaus set a $115.00 price target on Zimmer Biomet and gave the company a "buy" rating in a report on Tuesday, May 6th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $113.45.

Zimmer Biomet Stock Performance

ZBH traded down $0.56 during midday trading on Tuesday, reaching $95.21. The company had a trading volume of 2,330,698 shares, compared to its average volume of 1,760,828. The business has a 50-day moving average of $103.24 and a two-hundred day moving average of $105.76. The company has a market cap of $18.84 billion, a P/E ratio of 21.40, a P/E/G ratio of 1.95 and a beta of 0.78. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.92 and a 1 year high of $120.13. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. The company had revenue of $1.91 billion during the quarter, compared to the consensus estimate of $1.89 billion. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. Zimmer Biomet's quarterly revenue was up 1.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.94 EPS. As a group, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st were issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.01%. The ex-dividend date of this dividend was Monday, March 31st. Zimmer Biomet's dividend payout ratio (DPR) is presently 21.24%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.